TCM for Fatty Liver (MASLD): Damp-Heat, Spleen Deficiency, Acupressure Points, Food Therapy, and When to See a Doctor (2026 Guide)

Cover image source: Pexels

It is late September 2026, just past the autumn equinox, and your checkup flags ALT or AST in red while the ultrasound report says “fatty liver.” You feel fine: this is usually a silent diagnosis. Shorter days, less movement, and more comfort eating make autumn a useful moment to review your routine. Start with our autumn wellness guide, then give this finding a medical follow-up plan.

What fatty liver is called now

The AASLD nomenclature guide explains the 2023 AASLD/EASL/ALEH multisociety Delphi consensus: SLD, steatotic liver disease, is the umbrella; MASLD, metabolic dysfunction-associated steatotic liver disease, replaces NAFLD; MASH replaces NASH. The change addresses exclusionary, stigmatizing language and uses positive criteria: liver fat plus at least one cardiometabolic risk factor.

MetALD recognizes combined metabolic and alcohol-related disease, beginning around weekly alcohol thresholds of 140 g for women and 210 g for men. Still higher consumption can indicate primarily alcohol-associated disease; these thresholds are not safe-drinking targets.

NIDDK’s older NAFLD estimates put U.S. adult prevalence at 24%, with NASH at 1.5%–6.5%. NAFLD affects approximately one-third to two-thirds of people with type 2 diabetes, up to 75% of people with overweight, over 90% with severe obesity, and approximately 10% of U.S. children aged 2–19. Cardiovascular disease is the leading cause of death.

A global epidemiology review reports approximately 38% adult prevalence and 7%–14% among children and adolescents, with further increases expected. These estimates reflect different populations and periods. Lean MASLD exists; Asian populations often develop it at lower BMI.

NIDDK describes few or no symptoms, sometimes fatigue or right upper abdominal discomfort. Feeling well does not exclude disease. Our liver health guide covers broader background.

TCM patterns are an interpretive framework

Ancient Chinese medicine had no ultrasound diagnosis called fatty liver. Contemporary practitioners interpret it through metabolic, phlegm-dampness, and flank-discomfort frameworks.

A 2026 review of TCM for diabetes with MASLD describes phlegm-dampness, damp-heat, liver depression or qi stagnation, and spleen deficiency. These are traditional pattern concepts, not measurements of liver fat or anatomical spleen failure.

The same ultrasound finding can accompany different patterns. A qualified TCM practitioner must assess you in person; an online symptom checklist cannot select your herbs. Standardization remains weak: the 2025 herbal evidence overview found that 83.8% of 37 reviews omitted syndrome criteria, including definitions of liver-stagnation and spleen-deficiency.

Herbal evidence: promising signals, insufficient certainty

That overview summarized 37 systematic reviews/meta-analyses. Reported trends included ALT −8.2 U/L (95% CI −10.1 to −6.3), triglycerides −0.5 mmol/L, and ultrasound improvement RR 1.62. However, 35 reviews had low or critically low methodological quality; GRADE rated 92.5% of outcomes low or very low. The authors explicitly advised against clinical translation of current findings.

Its account of the earlier Dai overview reported ALT MD −3.2 U/L (95% CI −6.5 to 0.1; I² = 68%); 5 of 8 reviews were nonsignificant. Small samples, inconsistent formulations, and heterogeneous results prevent reliable treatment conclusions.

Xiaoyao Powder and Danning Tablet are frequently highlighted formulas in this literature, alongside approaches described as strengthening the spleen, transforming phlegm, and removing stasis. Mention frequency is not proof of benefit.

For milk thistle, or silymarin, NCCIH reports conflicting or inconclusive findings. Its funded hepatitis C and NASH trials found no benefit.

Herbs can also injure the liver

LiverTox identifies Polygonum multiflorum, also called Fo-Ti or Shou Wu Pian, as China’s most common reported cause of herbal liver injury. In a hospitalized drug-induced liver injury series, 29 of 547 cases involved this herb; 79% developed jaundice and one patient died. Among clinically apparent reported cases, up to approximately 10% died or needed urgent transplantation. This is not the risk among all users.

HLA-B*35:01 appeared in 70%–88% of cases versus 5% of controls. The reaction is idiosyncratic, without a clear dose relationship. A small dose is no guarantee of safety. LiverTox’s broader review also lists reports involving Ba Jiao Lian, Jin Bu Huan, Ma Huang/Ephedra, and Chi R Yun.

NIDDK warns that some herbal remedies damage the liver. Discuss every supplement or alternative treatment with your doctor. Herbal prescribing requires qualified TCM assessment: do not buy formulas for prolonged self-treatment, and never independently stop prescribed medication.

Acupuncture: what the pooled results actually show

The 2025 Medicine meta-analysis, 104(18):e42272, included 30 studies. Its clinical effective rate favored acupuncture: OR 3.36 (95% CI 2.62–4.31; I² = 0%). ALT showed SMD −0.51 (95% CI −0.59 to −0.43; I² = 41%); AST showed SMD −0.51 (95% CI −0.70 to −0.32; I² = 73%), across 21 studies and 1,693 participants.

Subgroup ORs were 3.14 for thread embedding, 3.27 for manual acupuncture, 3.32 for electroacupuncture, and 5.74 for point injection. These are not head-to-head rankings. No obvious adverse reactions were observed during the trials; larger rigorous randomized trials remain necessary.

The 2021 Medicine review, 100(38):e27050, included 8 randomized trials and 939 participants. Effective-rate ORs were 3.19 (95% CI 2.06–4.92) versus conventional medication and 5.11 (95% CI 2.43–10.75) for acupuncture plus medication versus medication alone. BMI did not decrease. LR3, ST36, ST40, and SP6 were most common.

In the newer review, point-use counts were ST36 (27), ST40 (18), SP6 (17), LR3 (14), BL18 (11), CV12 (10), GB34 (8), PC6 (6), ST25 (4), BL20 (4), and SP9 (3).

These largely Asian trials had modest samples, generally short follow-up under 6 months, and weak blinding. “Clinical effective rate” is a composite soft outcome, not proof of reduced liver fat. OR means odds ratio; SMD is standardized mean difference, not U/L.

NCCIH’s acupuncture review supports benefits for some pain conditions but describes uncertain mechanisms and nonspecific, including placebo, effects; real and sham acupuncture sometimes perform similarly. Its TCM safety guidance warns that poor technique can cause infection, pneumothorax, or organ puncture. Use qualified practitioners.

Gentle acupressure at home

Needle-acupuncture results do not establish that finger pressure treats MASLD. Use acupressure for a calming routine, not as a liver-fat treatment.

Use a thumb or finger pad for steady pressure, breathe slowly, and alternate sides on paired points. Aim for mild aching fullness without pain; stop if uncomfortable. Locations below are approximate body-relative landmarks, not needling instructions.

During pregnancy, avoid strong SP6 and LI4 pressure and ask your clinician first. Do not press broken, infected, or inflamed skin. Leave strong pressure over back points BL18/BL20 to qualified professionals. If taking anticoagulants, avoid forceful pressure that causes bruising.

Food therapy starts with established nutrition

NIDDK’s treatment guidance states that losing 3%–5% of body weight reduces liver fat; improving inflammation and fibrosis may require 7%–10%. Lose weight gradually: rapid loss and malnutrition can worsen liver disease.

Build meals around vegetables, beans, whole grains, olive oil, and fish. This Mediterranean-style approach fits the AGA pathway. Reduce sugary drinks and ultra-processed foods. NIDDK discusses research linking high-fructose intake to disease; target concentrated added-sugar sources. MedlinePlus also emphasizes healthy eating and weight management.

Traditional food theory, not modern nutritional evidence: dampness-oriented advice includes bitter greens, winter melon, coix seed, lotus leaf, hawthorn, white radish, and green tea, while limiting greasy, sweet foods and alcohol. Autumn practice favors warm cooked meals over cold raw foods. None is proven to lower your liver enzymes. Medicinal ingredients need the same interaction review as other herbal products.

Use our TCM diet principles and food-therapy soup guide for meal ideas, keeping nutrition and portions central.

Exercise helps before the scale changes

An aerobic-exercise review of 15 randomized trials reported intrahepatic triglyceride reduction: MD −4.06 (95% CI −5.37 to −2.74; p < 0.0001), with 190 participants contributing to that analysis. Different intensity/frequency combinations appeared similarly effective.

A resistance-training review included 11 randomized trials and 395 participants. ALT fell by MD −4.44 U/L (95% CI −8.84 to −0.03; P = 0.05); AST did not significantly change. Liver fat decreased significantly in 7 of 8 imaging studies, with no serious adverse events reported.

Its proposed program uses 8–10 whole-body, multijoint exercises at 60%–80% of one-repetition maximum, at least 3 times weekly for at least 12 weeks. Build toward this with instruction, especially if aerobic exercise is difficult.

The U.S. physical activity guidelines recommend at least 150 minutes of moderate activity weekly, spread across days. Exercise benefits do not have to wait for weight loss.

Keep medical testing and treatment central

Review ALT/AST, blood count including platelets, glucose, lipids, and abdominal ultrasound. Fibrosis means scarring; noninvasive assessment determines who needs specialist care.

FIB-4 uses age, AST, ALT, and platelets. The AGA pathway supports initial FIB-4 screening followed by liver stiffness or ELF blood testing:

• Below 1.3, or below 2.0 at age 65 and above: low risk; primary-care follow-up and repeat FIB-4 every 1–2 years.
• 1.3–2.67: an indeterminate range requiring second-line testing, such as VCTE liver stiffness or ELF, with the age adjustment above.
• At or above 2.67: high risk; refer to hepatology.

Liver stiffness below 8 kPa generally indicates low risk; 12 kPa or higher suggests advanced fibrosis. Intermediate results also require assessment: do not wait for the higher threshold before seeking follow-up.

Diet and exercise remain first-line. The FDA granted accelerated approval to resmetirom (Rezdiffra) on March 14, 2024, for adults with noncirrhotic MASH and F2–F3 fibrosis, alongside diet and exercise. The phase III MAESTRO-NASH program enrolled 1,759 participants; approval relied on an interim analysis, with completion of the 54-month confirmatory trial required. Standard prescribed dosing is once daily: 80 mg below 100 kg and 100 mg at or above 100 kg. The prescriber checks interactions and monitoring needs.

Drink less alcohol; beverage choice matters less than total exposure. Manage blood pressure, glucose, and lipids together because cardiovascular disease is the leading mortality risk. See our diabetes and blood-sugar guide for related self-care.

Warning signs that need action

MASLD is usually silent. You cannot judge improvement or deterioration by how you feel.

A seven-day rhythm you can start now

• Twice daily, gently press LR3 and ST36 for 1–2 minutes each, observing the precautions above.
• Walk briskly for 25–30 minutes daily.
• Replace dinner’s sugary drink with water or unsweetened tea.
• Start with two resistance sessions this week; build toward the research program above.
• Go to bed 30 minutes earlier.
• Put your next blood test and medical appointment on the calendar.

Put the priorities in order

Diet, exercise, scheduled testing, and clinician-directed treatment come first. TCM can contribute pattern-informed food choices, routines, and complementary care. It cannot replace diagnosis, fibrosis assessment, or treatment. Track your follow-up results rather than chasing a detox promise.